- Larimar Therapeutics Inc To Provide a Program Update TranscriptFeb 12, 2024
- Larimar Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference TranscriptNov 07, 2023
- Larimar Therapeutics Inc To Discuss Phase 2 dose exploration trial of CTI-1601 TranscriptJul 25, 2023
- Larimar Therapeutics Inc CTI-1601 May 2023 Program Update Conference Call TranscriptMay 15, 2023
- Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) TranscriptApr 04, 2023
- 9Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Immunology and Neurology Day TranscriptNov 15, 2022
- Larimar Therapeutics Inc To Discuss Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 TranscriptSep 14, 2022
- Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Q1 2021 Larimar Therapeutics Inc Earnings Call TranscriptMay 11, 2021$8.36 (-36.28%)Earnings
- Zafgen Inc and Chondrial Therapeutics Announce Definitive Merger Agreement - M&A Call TranscriptDec 18, 2019
- Q4 2018 Zafgen Inc Earnings Call TranscriptMar 11, 2019Earnings
Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Good afternoon, and welcome back to the William Blair Biotech Focus Conference of 2021. This is one of the last sessions of the day -- last but not least. So my name is Myles Minter, I'm a senior biotech analyst here at the firm covering neurosciences and other areas. Before we get started on this fireside chat with Larimar Therapeutics, I will refer you to disclosures available on williamblair.com just in case there is any forward-looking statements being made today. In addition to that, there is a question-and-answer box below. If you submit your questions there, I will do my best to get them addressed throughout the chat today.
With those formalities out of the way, it is my pleasure to introduce Carole Ben-Maimon, who is the CEO of Larimar Therapeutics -- Chondrial prior to the Zafgen merger as well. So welcome and thank you very much for joining us today, Carole. I guess for just all the listeners on the call, the majority, I believe, will be familiar with the story. But for those who aren't, can you just give us an update on the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)